Day: July 8, 2026

Meltwater Expands Access to Meltwater MCP Bringing Actionable Intelligence Into the AI Tools Teams Already Use

by

Meltwater MCP is the only full-suite media intelligence platform that plugs directly into leading AI assistants, custom agents and AI workflows – with the ability to take action, not just answer questions

SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) — Meltwater, the global leader in actionable intelligence for PR, Communications and Marketing teams, today announced a major expansion of Meltwater MCP (Model Context Protocol). The release adds a new set of MCP tools that allow AI assistants to take action inside the Meltwater platform, helping teams access insights, create reports, and track alerts in real time.

Ask Meltwater, Inside Existing AI Tools

Meltwater has hosted MCP natively since June 2025, bringing unmatched real-time, cited media, social, and influencer intelligence directly into the AI tools teams already use. This allowed users to ask questions in plain language and receive trusted answers grounded in Meltwater’s licensed data which analyzes 1.3 billion-plus documents a day.

But teams no longer want AI assistants that simply summarize information. They want agents that can understand intent, work with trusted context, take action and learn from the intelligence assets a team has already built.

Meltwater MCP meets this need, moving beyond simply answering questions to allow AI tools to build on existing projects within the Meltwater platform. Teams can simply ask their preferred AI tool for an overview of breaking news coverage, a brand health report, or a brief on trending social media topics, without having to log in to Meltwater and start a search from scratch. The results can be saved, re-used and referenced again by an AI agent that knows the purpose behind them.

Access to Trusted Intelligence Across Your Organization

Not everyone who needs a Meltwater answer has platform access, so they often turn to generic AI tools that respond from open-web data rather than trusted, sourced intelligence. This means that generic results often sound confident while being outdated, incomplete, or simply wrong. Meltwater MCP closes this gap with a single, governed connector that brings Meltwater’s licensed data into any compatible AI assistant, letting teams ask questions in plain language and get cited, verifiable answers without a custom integration or specialist help.

“Intelligence shouldn’t require a specialist to unlock it,” said Chris Hackney, Chief Product Officer at Meltwater. “Meltwater MCP means the analyst, the executive, and the intern can all ask the same question and get the same quality of answer, grounded in real Meltwater data, right inside the AI tools they already use every day.”

“Teams shouldn’t have to pick between the AI tool they already love using and the data they actually trust, but that’s the tradeoff most integrations force on them,” said Aditya Jami, Chief Technology Officer at Meltwater. “Meltwater MCP means they don’t have to. It’s one connector, fully governed, bringing real Meltwater intelligence into whichever assistant a team is already using. And now, they can act on it too, not just ask about it.”

Now Generally Available to Meltwater Customers

Meltwater MCP is now generally available to Meltwater customers. It builds on more than a year of customer pilots and provides MCP-based access to its data and content in production. The release reflects Meltwater’s commitment to empowering leaders with the intelligence they need to set a new standard in PR, Communications, and Marketing.

To learn more about Meltwater’s MCP offering, visit meltwater.com.

For more information, please contact:
Kelly Costello
Corporate Communications Director
[email protected]

About Meltwater
Meltwater is the global leader in actionable intelligence for PR, Communications, and Marketing teams. By analyzing 1.3 billion pieces of content daily, Meltwater transforms media, social, and AI signals into intelligence that leaders rely on to make faster, more confident decisions. With 27,000 customers worldwide, Meltwater is the intelligence platform global brands trust to stay ahead.

Meltwater: Intelligence you can act on. 
Learn more at meltwater.com.

GlobeNewswire Distribution ID 9758635

Anaqua Renews Partnership with Sony to Advance IP Innovation

by

TOKYO, July 07, 2026 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology solutions and services, today announced the renewal of its partnership with Sony Group Corporation (“Sony”). Under this agreement, Anaqua will support Sony in strengthening intellectual property as a core driver of its business strategy, innovation, and global growth. Anaqua was first selected by Sony as its IP management platform in 2018.

The renewal of this partnership reflects Sony’s evolving business strategy and the growing importance of intellectual property intelligence across its integrated operations. Anaqua will continue to support the consolidation and integration of Sony’s IP management across its patents, designs, trademarks, and related rights for its global, cross-business units.

Sony, which operates across diverse businesses: Games & Network Services, Music, Pictures, Entertainment Technology & Services, Imaging & Sensing Solutions, is one of the largest patent filers globally in its core technologies, such as gaming and imaging technologies. Furthermore, its portfolio consistently ranks among the most cited in those same fields, a widely recognized benchmark of genuine innovation. Sony’s IP portfolio is as expansive as it is strategically vital.

With the renewed agreement, Anaqua will continue to provide Sony with the AQX® platform, AcclaimIP analytics solution, and Patent and Design Annuities and Trademark Renewals services, while Sony actively evaluates and adopts Anaqua’s advanced AI-powered capabilities, which aligns with its transformation objectives. These include AI solutions designed to deliver deeper insights, faster strategic planning, and stronger brand and innovation governance.

“The pace of innovation is accelerating like never before,” said Asashi Shimodaira, Head of IP and Technology Standardization, Sony Group. “Efficiency is crucial, and that’s one of the key reasons why we chose Anaqua. The latest version with AI-powered functions promises significant process improvements. We aim to free up time for more strategic thinking.”

Through this strengthened collaboration, Anaqua will support Sony in shifting how the company uses IP: transitioning from traditional protection to a portfolio-driven, data-centric approach that informs decision-making across business units, accelerates innovation cycles, and supports emerging technologies and new market opportunities with Anaqua’s AQX platform.

“Sony has consistently been at the forefront of reimagining how intellectual property supports business growth,” said Justin Crotty, CEO of Anaqua. “From our initial partnership to our evolving, long-term collaboration, we’re proud to support Sony with AI-driven technologies that help turn IP into a powerful engine for innovation and competitive advantage.”

“Sony has a clear vision for elevating IP as a driver of business growth and global competitiveness,” said Kazuyasu Adachi, president and general manager, Japan & APAC, Anaqua. “The strong partnership with Sony underscores Anaqua’s longstanding commitment to supporting global enterprises operating across complex, multi-business environments and global regions. By integrating agreements across Sony entities and standardizing platforms and data, Sony is positioned to scale best practices, improve collaboration, and continuously refine IP strategy in a rapidly changing global landscape.”

Anaqua supports Sony with a globally coordinated, cross-functional team that delivers deep technical expertise and a consistently high-quality experience across Japan and worldwide. By seamlessly integrating its local Japan team with its global organization, Anaqua provides tailored, region-specific support while ensuring alignment across markets. Insights from close collaboration in Japan help optimize Sony’s operations and user experience, while Anaqua’s global perspective drives continuous improvement at scale, delivering responsive, localized support and consistent excellence wherever Sony operates.

About Sony Group Corporation
To find out more about Sony, please visit https://www.sony.com/en/.

About Anaqua
Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software platforms, AQX®, PATTSY WAVE®, and RightHub® offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s needs. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over two million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on Anaqua’s LinkedIn.

Media Inquiries:
[email protected]
+1-617-375-5808

GlobeNewswire Distribution ID 9757777

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

by

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 million
CMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively

Mont-Saint-Guibert, Belgium – July 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results.

Second Quarter 2026 – Preliminary Sales and Market Metrics

  • Financials
    • Global net revenue is expected to be approximately €7.7 million in the second quarter of 2026, which reflects 21% sequential growth over the first quarter of 2026
    • U.S. net revenue is expected to be approximately €5.2 million in the second quarter of 2026, which reflects 22% sequential growth over the first quarter of 2026
  • Leading U.S. commercial indicators
    • 55 new surgeons trained in Q2, bringing the total to 262 surgeons trained
    • 89 new accounts activated in Q2, bringing the total to 180 active high-volume accounts
    • 427 patients submitted under prior authorization entering Q3
  • Reimbursement US
    • CMS is proposing to increase hospital reimbursement for the Genio procedure (C8011) from $31,526 to $35,414, representing an increase of $3,888 (12%)
    • CMS is proposing to increase ASC reimbursement from $27,563 to $31,722, an increase of $4,159 (15%)
  • Liquidity
    • $110 million in aggregate financing secured in Q2
    • As of June 30, 2026, cash, cash equivalents and financial assets are expected to be approximately €97.8 million

“We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth. Additionally, the recent CMS proposed reimbursement increases in both hospital outpatient and ambulatory surgical centers are among the strongest within APC 5465 (Level 5 Neuromodulation) and, if approved, support continued economic value for the Genio procedure,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “With $110 million in new financing, the financial overhang is now behind us, and we are positioned to accelerate Genio’s U.S. commercial ramp and drive toward profitability.”

Revenue Guidance for the Full Year 2026 

  • The Company continues to expect global net revenue for the full year 2026 to be in the range of €36 million to €40 million.

The preliminary, unaudited revenue results and cash, cash equivalents and financial assets described in this press release are estimates only and are subject to revision until Nyxoah reports its full financial results for the second quarter of 2026, including in its Quarterly Report on Form 6-F.

Upcoming Investor and Analyst Day

The Company will be hosting an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET).

The event will be webcast live for those unable to attend in person, with a replay available shortly afterwards. Participants joining via the webcast will be able to ask questions during the event.

Event details

  • Date: Wednesday, July 8, 2026
  • Time: 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET)
  • Location: Bank of America Tower at One Bryant Park, 1111 Avenue of the Americas, New York, NY
  • Registration and webcast access:

https://www.netroadshow.com/events/login/1PeTHmohOsvcptHhJ0ULn0T429N8JKb3IuZtL

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company’s commercialization strategy and entrance to the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment

GlobeNewswire Distribution ID 1001211720